Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer
Clinical trial NCT02023359 · COMPLETED
Trial details
- NCT number
- NCT02023359
- Sponsor
- Novartis Healthcare A/S
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2013-12-01
- Primary completion
- 2015-04-01
- Enrollment
- 7
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.